Inflammation

Researchers analyzed numerous biomarkers in patients at risk for inflammatory arthritis to develop measurable scores indicating a patient's vulnerability to disease progression.

New research suggests that measuring the inflammatory marker myeloperoxidase (MPO) may be an effective strategy for the prediction of patients' risk of mortality in a myriad of cardiac—and potentially non-cardiac—diseases.

With data on side-opening cutting forceps showing above a 90% diagnostic rate for tissue biopsy in adult patients with eosinophilic esophagitis (EoE) who undergo biopsy of the esophageal lamina propia (ELP), investigators conducted a pilot study on use of side-opening cutting forceps in younger patients.

A study from China suggests calcium and magnesium malnutrition is associated with Crohn's disease inflammation and activity.

The current literature is lacking on outcomes among patients with comorbid chronic rhinosinusitis (CRS) and immunoglobulin deficiencies, especially for those who must use surgery to manage their CRS.

With this study, investigators hoped to advance their understanding of cellulitis-mimicking reactions among patients currently receiving chemotherapy.

Few validated measures exist to quantify sleep disturbance among patients who have the chronic inflammatory skin condition prurigo nodularis.

Outcomes of concern for this retrospective study were eosinophilic esophagitis (EOE) mucosal biopsies, EoE diagnosis, proton pump inhibitor initiation, and recommendations being followed for repeat esophagogastroduodenoscopy.

Higher levels of fractional exhaled nitric oxide (FeNO) were found in patients with eosinophilic esophagitis (EoE) and might be able to provide a measurement of clinical treatment response in a subset of these patients.

Scientists have found a new therapy for the severe inflammatory skin disorder.

More geographically and racially diverse population cohorts are needed to determine heritability risk in chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRS).

Investigators evaluated long-term outcomes among individuals who have eosinophilic esophagitis (EoE) and initiated first-line treatment with a food elimination diet after experiencing remission following stoppage of proton pump inhibitor monotherapy.

Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.

The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis.

In the phase 3 SINUS-24 and SINUS-52 trials, dupilumab improved clinical outcomes and and health-related quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease.

Treatment with dupilumab demonstrated improvements in histological markers, symptoms, and endoscopic markers of eosinophilic esophagitis (EoE) regardless of previous history of esophageal dilation.

Dupilumab treatment delivered at a specialized tertiary care center has great potential to improve patient clinical outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP).

Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are type 2 inflammatory conditions that frequently coexist, the with the latter increasing the symptom burden of the former

Investigators wanted to assess endoscopic appearance, wall thickness, histology, and dysphagia score for eosinophilic esophagitis (EoE).

A study explored outcomes among patients living with newly diagnosed eosinophilic esophagitis (EoE) who demonstrated lack of histological response following proton pump inhibitor (PPI) treatment.

Health status and health-related quality of life (QOL) outcomes were compared between patients with severe cases of chronic rhinosinusitis with nasal polyps (CRSwNP) and a general patient population.

Exposure to pets during fetal development or early infancy was associated with reduced instances of food allergies in young children, with different pet exposures potentially reducing the incidence risk of certain allergen types.

A research letter highlighted recent findings that iREACH educational intervention training may be helpful in preventing peanut allergies.

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the monoclonal antibody for the chronic inflammatory skin condition.

Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.

The Skin Pain Numeric Rating Scale, Worst-Itch Numeric Rating Scale, and Dermatology Life Quality Index were evaluated for their content validity, fit-for-purpose, and psychometric and measurement properties among patients with the chronic skin disease being treated with dupilumab.

Using a clustering algorithm, researchers were able to identify inflammatory and noninflammatory subsets of the disease, which may account for varying responses to certain treatments.

The supplemental Biologics License Application was filed for the new indication for dupilumab, which is already approved to treat atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.

The 2 therapies, a 1-food and a 6-food elimination diet both used for eosinophilic esophagitis (EoE), were compared for outcomes after 6 weeks.

In this analysis, evidence was reviewed for the effectiveness of intranasal corticosteroids, biologics, and aspirin therapy after desensitization use among patients who have chronic rhinosinusitis with nasal polyposis (CRSwNP).